OST and MORES in Male Osteoporosis (OST and MORES)

Performance of the Osteoporosis Self-Assessment Tool (OST) and Male Osteoporosis Risk Estimate Score (MORES) in Predicting Osteoporosis in Turkish Men

The aim of this study is to compare the Male Osteoporosis Risk Score and the Osteoporosis Self-Assessment Tool with the gold standard DEXA in determining the risk of osteoporosis in the lumbar and femoral regions in male individuals in the Turkish population, and to investigate their sensitivity and specificity in the first stage of screening for the detection of male osteoporosis.

Study Overview

• Status: Active, not recruiting
• Conditions: Male Osteoporosis

Detailed Description

This study will be conducted as a single-center, retrospective study at the Physical Medicine and Rehabilitation Clinic of Kayseri City Hospital between January 2024 and January 2025. Male patients aged 50-75 who underwent osteoporosis screening with DEXA between January 2021 and January 2024 at the FTR outpatient clinics of Kayseri City Hospital will be included in this study. Patient data will be obtained retrospectively from the hospital database. Sociodemographic data (age, height, weight, body mass index) and current laboratory data (complete blood count, biochemical values (fasting blood sugar, BUN, creatinine, AST, ALT, calcium, phosphorus, alkaline phosphatase, total protein, albumin, parathyroid hormone, vitamin D3, T4, TSH), and DEXA values (bone mineral density, lumbar vertebrae, and total T scores for the femoral neck and femur) will be recorded. The OST score will be calculated using body weight and age parameters. The MORES score will be calculated based on age, weight, and hospital data, specifically the presence of chronic obstructive pulmonary disease (COPD) with ICD-10 code: J44 and its subgroups.

The data will be evaluated using the SPSS 24.0 software package. Descriptive statistical analyses will include calculations of mean, standard deviation, frequency, and percentages. In comparative statistics, the Student's t-test or Mann-Whitney U test will be used to compare independent groups. Chi-square analysis will be applied to compare categorical variables. Pearson or Spearman correlation analyses will be applied to evaluate the relationship between variables. Both groups will be compared, and p<0.05 will be considered statistically significant.

• Study Type: Observational
• Enrollment (Estimated): 140

Contacts and Locations

Study Locations

• Turkey (Türkiye)
  • Kayseri
    • Kayseri, Kayseri, Turkey (Türkiye), 38050
      • Kayseri City Education and Research Hospital

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

• Sampling Method: Probability Sample

Study Population

This study will be conducted retrospectively at the Physical Medicine and Rehabilitation Clinic of Kayseri City Hospital between January 2024 and January 2025. This study will include male patients aged 50-75 who underwent osteoporosis screening with DEXA at the Kayseri City Hospital Physical Medicine and Rehabilitation outpatient clinics between January 2021 and January 2024.

Description

İnclusion criteria:

• Men aged 50-75
• Patients who underwent imaging with the STRATOS DEXA device at Kayseri City Hospital

Exclusion criteria:

• Patients younger than 50 or older than 75 years of age
• Patients with secondary osteoporosis
• Female patients
• Patients with uncontrolled severe comorbid conditions
• Patients with a history of pathological fractures

Study Plan

How is the study designed?

Number of groups / cohorts

1

Cohorts and Interventions

Group / Cohort
male osteoporosis group

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Dual energy Xray Absorptiometry (DEXA)	DEXA measures bone mineral density (BMD; g/cm2) based on the scanned bone area. T and Z scores are used to interpret DEXA results. The T score indicates how many standard deviations below or above the average BMD measurements of a patient of the same gender and younger adults. The T score should be used for the diagnosis of osteoporosis in postmenopausal women and men over 50 years of age. The Z score indicates how many standard deviations below or above the average BMD measurements of the same gender and age. The Z score should be used for the diagnosis of osteoporosis in premenopausal women and men under 50 years of age. According to the World Health Organization's definition of bone mineral density: A T score between -1 and -2.5 SD indicates osteopenia.; A T score below -2.5 SD indicates osteoporosis.; A T score below -2.5 SD accompanied by a fragility fracture(s) indicates severe osteoporosis. • A Z-score of -2.0 SD or lower is defined as "below the expected range for age,"	January 2021-January 2024
MORES	The Male Osteoporosis Risk Prediction Score uses age, weight, and history of chronic obstructive pulmonary disease (COPD) to classify the risk of osteoporosis in men aged 50 and older. Values of 6 or higher are the threshold for screening.	January 2021-January 2024
OST	The Osteoporosis Self-Assessment Tool (OSA) screening program is used to improve osteoporosis screening in patients. The main tool of this screening program is the OS, a risk formula based on age and weight. OS has proven to be a reliable screening tool for osteoporosis in both female and male populations. The OS score is calculated using the formula: OST Score = [Weight (kg) - Age] x 0.2. Osteoporosis risk: High risk: -20 to -4 for women, -20 to -1 for men; Moderate risk: -4 to -1 for women, -1 to 4 for men; Low risk: -1 to 20 for women, -4 to 20 for men	January 2021-January 2024

Collaborators and Investigators

• Sponsor: Kayseri City Hospital
• Investigators: Principal Investigator: Fatma Gül Ülkü Demir, MD, Kayseri City Hospital

Study record dates

Study Major Dates

• Study Start (Actual): February 4, 2026
• Primary Completion (Estimated): July 1, 2026
• Study Completion (Estimated): September 15, 2026

Study Registration Dates

• First Submitted: February 4, 2026
• First Submitted That Met QC Criteria: April 4, 2026
• First Posted (Actual): April 8, 2026

Study Record Updates

• Last Update Posted (Actual): April 8, 2026
• Last Update Submitted That Met QC Criteria: April 4, 2026
• Last Verified: April 1, 2026

More Information

Terms related to this study

• Keywords: OST; male ostoporosis; MORES; osteoporosis risk estimation
• Other Study ID Numbers: Male osteoporosis

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: UNDECIDED
• IPD Plan Description: There is not a plan to make IPD available.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No